A phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastoma
{{output}}
Background: Gallium maltolate is an oral compound that disrupts iron-dependent glioblastoma (GBM) growth and prolongs survival in animal models. This Phase 1 trial of oral gallium maltolate in patients with recurrent GBM was cond... ...
